Due to its unique properties, the current health care market poses challenges that may hinder widespread adoption and slow development of pharmacogenomics (PGx). Research conducted by Louis F. Rossiter, Ph.D., at the Schroeder Center for Healthcare Policy at the College of William & Mary, examined the current market system to determine whether or not PGx could flourish in the current financing, delivery, and payment environment. According to Rossiter, “PGx products and services may be used inefficiently because the current system relies more on a trial and error approach, rather than on an individualized one which is offered by PGx.” Additionally, PGx faces challenges in the way of competition from large pharmaceutical firms, the absence of a “blockbuster drug” to motivate investment in research and development, and a lack of cost-effectiveness studies that could encourage adoption and public and private reimbursement of products and services.
To download a full copy of the Findings Brief, please visit the HCFO Web site.
